Unbiased Analysis of Today's Healthcare Issues
Today, the American Cancer Society’s Cancer Action Network released a report titled “Out of Pocket Costs for Follow-Up Tests After Abnormal Screening Mammogram and Their Impact on Breast Cancer Survival.” The empirical analysis was conducted by myself and some colleagues at FTI Consulting (Shanshan Wang, Shurui Zhang, Citseko Staples Miller, and Sophia Mildred Setterberg). An…
Here is the list of my papers that were published in 2024. Manuscripts were published in Value in Health, BMJ Open, Journal of Comparative Effectiveness Research, Forum for Health Economics and Policy, Annals of the American Thoracic Society and others. Links to all papers are below. Clayton D, Shafrin J, Yen GP, Geevarghese L, Shi…
That is the title of an interview with me in The Evidence Base out today with the subtitle Introducing generalized cost effectiveness analysis for a comprehensive value assessment. Below is an excerpt: What is this paper about? What is new in this paper?Our recent publication presents a comprehensive framework for evaluating the societal value of health technologies,…
That is my recent paper with co-authors Shanshan Wang, Jason Shafrin, and Kirk Kerr in BMJ Open. The abstract is below: Objective To estimate the health economic value of postdischarge oral nutrition supplement (ONS) consumption among elderly adults who were malnourished during hospitalisation. Design A cost-effectiveness model was developed from a US payer perspective based on a…
I will be presenting two panels at ISPOR Europe 2024 in Barcelona next week! This year’s conference theme centers on the importance of scientific evidence in understanding and improving the health and well-being of people across the globe. Panel 1: Broader Value Elements: Methods to Quantify Each and Their Relevance for European Markets Monday, Nov…
That is the title of a new publication with co-authors Joshua T. Cohen, Louis P. Garrison, Dana A. Goldman, Jalpa A. Doshi, Joshua Krieger, Darius N. Lakdawalla, Peter J. Neumann, Charles E. Phelps, Melanie D. Whittington and Richard Willke. This consensus paper aims to provide researchers with a user guide for estimating broader societal value…
That is the title of my recent paper with co-authors Denise Clayton, Glorian Yen, Lincy Geevarghese, Yulin Shi Anem Waheed. The abstract is below. IntroductionParoxysmal nocturnal hemoglobinuria (PNH) is a rare blood disease associated with complications that increase morbidity, such as thrombosis and chronic kidney disease. Limited data exist regarding complications among treated patients outside…
That is the title of a paper recently accepted for publication by Value in Health with co-authors Shanshan Wang, Khounish Sharma, Kathryn Spurrier, Robert J. Nordyke. The abstract is below. Objectives To identify the types of disease most likely to be impacted by the Institute for Clinical and Economic Review’s (ICER) shared savings assumptions. Methods…
Check out my new paper titled “Healthcare Stakeholder Perspectives on a Value Assessment Approach for Duchenne Muscular Dystrophy Therapies“. The abstract is below. Purpose: Traditional value assessment frameworks are challenged in comprehensively assessing the societal value new therapies bring to individuals with rare, progressive, genetic, fatal, neuromuscular diseases such as Duchenne muscular dystrophy (DMD). The…
That is the title of my new paper in Annals of the American Thoracic Society with co-authors David Ost, Fabien Maldonado, Jaehong Kim , Moises Marin, Tony Amos, Deanna Hertz, Iftekhar Kalsekar, and Anil Vachani. The abstract is below. Rational: While previous studies have assessed the clinical or economic value of specific technologies, the economic…